scholarly journals Quality of life, medication adherence and satisfaction with anticoagulant treatment (dabigatran vs vitamin K antagonists) according to thromboembolic risk. Data from the CAPANA study

2020 ◽  
Vol 74 (11) ◽  
Author(s):  
Vivencio Barrios ◽  
Carlos Escobar ◽  
Gonzalo Barón ◽  
Juanjo Gómez‐Doblas ◽  
Esther Recalde ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Anticoagulant Treatment ◽  
Thromboembolic Risk

Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists

2019 ◽  
Vol 219 (6) ◽  
pp. 285-292
Author(s):  
V. Barrios ◽  
C. Escobar ◽  
G. Barón Esquivias ◽  
J.J. Gómez Doblas ◽  
E. Recalde del Vigo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vitamin K ◽  
Vitamin K Antagonists

scholarly journals New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation

2014 ◽  
Vol 11 (7) ◽  
pp. 680-684 ◽  
Author(s):  
Josep M. Alegret ◽  
Xavier Viñolas ◽  
Miguel A. Arias ◽  
Antoni Martínez-Rubio ◽  
Pablo Rebollo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis

2003 ◽  
Vol 90 (07) ◽  
pp. 101-107 ◽  
Author(s):  
Mirjam Sprangers ◽  
Hanneke de Haes ◽  
Harry Büller ◽  
Martin Prins ◽  
Mirjam Locadia
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Venous Thrombosis ◽  
Vitamin K ◽  
Treatment Duration ◽  
Vitamin K Antagonists ◽  
Great Influence ◽  
Duration Of Treatment ◽  
Study Centre

SummaryIn clinical practice, decisions on the duration of treatment with vitamin K antagonists are usually based on the presence of persistent risk factors, the risk of bleeding and centre policy. Little is known about the influence of patients’ experienced quality of life. The objectives of this study were: 1) to explore the course of quality of life in patients with venous thrombosis treated for 3 months versus patients treated for 6 months with vitamin K antagonists; 2) to investigate the factors that were associated with the duration of treatment with vitamin K antagonists. The study sample comprised patients participating in a multi-centre clinical trial. Quality of life was assessed at study entry, after 10-14 days,3 and 6 months in 360 patients. Overall, no dif-ferences in quality of life were found between the 2 patient groups. An interaction effect between group and time was found for physical functioning. Regression analyses indicated that the presence of one or more permanent risk factors, duration of hospitalisation, mobility prior to deep-vein thrombosis and study centre were associated with the duration of treatment with vitamin K antagonists. Interestingly, quality of life was not associated with treatment duration. Since study centre was the most important factor associated with treatment duration, local policy appears to have a great influence on decisions regarding the duration of treatment with vitamin K antagonists.Part of this manuscript has been included in a poster presentation at the International Society for Quality of Life Research in Amsterdam, The Netherlands, November 8, 2001.

scholarly journals Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients

2016 ◽  
Vol 9 (4) ◽  
pp. 388-394 ◽  
Author(s):  
Hilde A.M. Kooistra ◽  
Margriet Piersma-Wichers ◽  
Hanneke C. Kluin-Nelemans ◽  
Nic J.G.M. Veeger ◽  
Karina Meijer
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Vitamin K ◽  
Prospective Cohort ◽  
Vitamin K Antagonists

Spectrophotometric Assays of Prothrombin in Plasma of Patients Using Oral Anticoagulants

1979 ◽  
Vol 42 (04) ◽  
pp. 1296-1305 ◽  
Author(s):  
R M Bertina ◽  
W van der Marel-van Nieuwkoop ◽  
E A Loeliger
Keyword(s):  
Prothrombin Time ◽  
Vitamin K ◽  
Oral Anticoagulation ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
Factor V ◽  
Anticoagulant Treatment ◽  
Factor Ii ◽  
K Deficiency

SummaryTwo spectrophotometric assays for prothrombin have been developed and compared with a one stage coagulant and an immunological assay. One of these assays (called the XAPC assay) uses a combination of factor Xa, phospholipid, Ca2+ and factor V as activator of prothrombin, and measures only normal prothrombin. The second (the ECAR assay) uses Echis carinatus venom as activator. This assay measures both normal prothrombin and PIVKA II (protein induced by vitamin K antagonists/absence). Combination of the results obtained by the XAPC and ECAR assays provides rapid and reliable information on the degree of “subcarboxylation” of prothrombin (oral anticoagulation, vitamin K deficiency).For patients on long term anticoagulant treatment the prothrombin time (Thrombotest) shows better correlation with the ratio prothrombin/prothrombin plus PIVKA II (XAPC/ ECAR) than with the factor II concentration. For patients starting the anticoagulant treatment there is no correlation between the Thrombotest time and the XAPC/ECAR ratio.It seems doubtful that (a) spectrophotometric factor II assay(s) will be as useful as the prothrombin time in the control of oral anticoagulation.

Sign in / Sign up

Export Citation Format

Share Document